Instrumenti kvaliteta života specifični za dermatologiju, sve češće se primenjuju u istraživanju kod pacijenata sa kožnim bolestima. CIlj je ispitati odnos ocena kvaliteta života dobijenih primenom dva za dermatologiju specifična instrumenta. Istraživanjem je obuhvaćeno 62 ispitanika sa kožnim bolestima, kod kojih je kvalitet života ocenjen primenom instrumenata specifičnih za dermatologiju (tj. Dermatology Life Quality Index-DLQI i Skindex-16), namenjenih upotrebi kod svih kožnih bolesti. Ukupni skorovi DLQI i Skindex-16 nalazili su se u jakoj korelaciji (r=0.87; p<0.001). Postojale su i statistički značajne korelacije ukupnog skora DLQI sa skorovima za podskale simptomi, emocije i funkcionisanje iz Skindex-16 instrumenta (r=0.53, r=0.77 i r=0.86, redom). Ukupan skor Skindex-16 nije bio u korelaciji sa skorom za podskalu tretman iz DLQI-a, međutim, bio je u korelaciji sa skorovima za podskale simptomi i osećanja, dnevne aktivnosti, slobodne aktivnosti, rad ili škola i lični odnosi iz DLQI-a (r=0.67, r=0.80, r=0.66, r=0.62 i r=0.68, redom). Dva instrumenta specifična za dermatologiju (npr. DLQI i Skindex-16), ukoliko se zajedno primenjuju, mogu pružiti komplementarne podatke pri ocenjivanju kvaliteta života pacijenata sa kožnim bolestima.

In diabetics fungal skin infections are reported to be related to greatly disturbed metabolism. In order to get better insight into the association between diabetes mellitus and fungal skin infections, we started our study with the aim to assess the effect of metabolic regulation on the incidence of fungal skin infections is diabetics. The obtained results of our study show that in patient with metabolically poorly regulated primary disease i.e. diabetes the incidence of the fungal skin infections is highest (36.0%), its incidence is lower in patients with metabolically satisfactorily regulated diabetes (29.5%) and lowest in those with well regulated diabetes (18.8%), witch is statistically significant difference (p=0.045).

The objective of this study that included 34 patients with psoriasis was to assess the reliability of the disease severity measures (i.e. Psoriasis Area and Severity Index - PASI) and the reliability of the health related quality of life measures (i.e. EuroQol EQ-5D Quality of Life Scale - EQ-5D, Dermatology Life Quality Index - DLQI and Psoriasis Disability Index -PDI). High interobserver correlation reliability and good test-retest reliability of PASI scores, as well as good test-retest reliability of EQ-5D, DLQI and PDI scores were achieved. Correlation coefficients between the test and retest scores on DLQI and PDI were higher than those on the dimensions and on EQ-VAS in EQ-5D. Disease severity scores given by PASI and the quality of lify scores given by EQ-5D, DLQI and PDI offered the reliable assessment of both the psoriasis severity and the quality of life of the people with psoriasis.